Private company

MARIZYME, INC.

MARIZYME, INC. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Jupiter, Florida.1

Last updated Oct 20, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersJupiter, Florida1
  • Incorporated inNV2
  • Business address555 Heritage Drive, Suite 205, Jupiter, Fl 334582
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

DuraGraft receiving its FDA clearance, Marizyme is now working toward its utilization and revenue generation in the United States.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

70.9%Gross margin4
-5278.1%Operating margin4
-10767.8%Net margin4
176.6%Revenue growth, 20234

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue8¢$188.1K
  • Research and development92¢$2.2M

Out of $645.8K in revenue.4 The company lost money this year.

Financial statements

Revenue56784$645.8K in 2023+538% since 2017
0$200.0K$400.0K$600.0K$800.0K2017: $101.2K$101.2K20172018: $20.2K$20.2K2018−80%2019: $0$020192020: $197.1K$197.1K20202021: $210.3K$210.3K2021+7%2022: $233.5K$233.5K2022+11%2023: $645.8K$645.8K2023+177%
Gross profit5684$457.7K in 2023+3108% since 2017
0$200.0K$400.0K$600.0K2017: $14.3K$14.3K20172018: $113$1132018−99%2019: $0$020192021: $129.9K$129.9K20212022: $179.2K$179.2K2022+38%2023: $457.7K$457.7K2023+155%
Operating income569784-$34.1M in 2023+27188% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$124.9K-$124.9K20172018: -$247.1K-$247.1K2018+98%2019: -$1.1M-$1.1M2019+328%2020: -$5.8M-$5.8M2020+448%2021: -$8.8M-$8.8M2021+52%2022: -$37.3M-$37.3M2022+323%2023: -$34.1M-$34.1M2023−9%
Net income569784-$69.5M in 2023+12089% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$570.5K-$570.5K20172018: -$248.7K-$248.7K2018−56%2019: -$1.1M-$1.1M2019+325%2020: -$5.8M-$5.8M2020+452%2021: -$11.0M-$11.0M2021+88%2022: -$38.2M-$38.2M2022+247%2023: -$69.5M-$69.5M2023+82%
Fiscal year2017201820192020202120222023
Revenue$101.2K5$20.2K6$06$197.1K7$210.3K8$233.5K4$645.8K4
Cost of revenue$86.9K5$20.1K6$06$80.4K8$54.3K4$188.1K4
Gross profit$14.3K5$1136$06$129.9K8$179.2K4$457.7K4
Research and development$687.7K7$1.7M8$4.0M4$2.2M4
Operating expenses$9.0M8$37.5M4$34.5M4
Operating income-$124.9K5-$247.1K6-$1.1M9-$5.8M7-$8.8M8-$37.3M4-$34.1M4
Interest$45.5K9
Net income-$570.5K5-$248.7K6-$1.1M9-$5.8M7-$11.0M8-$38.2M4-$69.5M4
Earnings per share-$0.318-$0.944-$1.534
Earnings per share (diluted)-$0.944-$1.534
Shares (weighted, basic)36.0M shares840.7M shares445.5M shares4
Shares (weighted, diluted)40.7M shares445.5M shares4

Compare MARIZYME, INC. with another company

Corporate structure

MARIZYME, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MARIZYME, INC.

  • Lichti Braeden Filed SC 13G on MARIZYME, INC., latest Jul 12, 2023
  • ESC Holdings LLC Filed SC 13G on MARIZYME, INC., latest Mar 31, 2023
  • MARIZYME, INC. Jupiter, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MARIZYME, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$12.5K4 Dec 31, 2023$12.5K4 Dec 31, 2022−0.4%
Operating-lease assets (leased space)$1.1M4 Dec 31, 2023$1.5M4 Dec 31, 2022−25.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$5.4M4 Dec 31, 2023$7.2M4 Dec 31, 2022−24.7%
Finite-lived intangibles, gross$29.1M4 Dec 31, 2023$53.5M4 Dec 31, 2022−45.5%
Accumulated amortization-$2.3M4 Dec 31, 2023-$1.5M4 Dec 31, 2022−57.3%
Finite-lived intangibles, net$14.4M4 Dec 31, 2023$27.7M4 Dec 31, 2022−48.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$24.9K4 Dec 31, 2023$215.6K4 Dec 31, 2022−88.5%

Leadership

Who has led MARIZYME, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Sandy J. Masselli Jr.2009
  2. Joerg Ott2010–2012
  3. Nicholas Devito2019
  4. James Sapirstein2020–2021
  5. Neil J. Campbell2020
  6. David Barthel2022

Chair

  1. Joerg Ott2012
  2. Vithalbhai D. Dhaduk2023

President

  1. Pui Shan Lam2008

Chief financial officer

  1. Vanleo Y.w. Fung2008
  2. Markus Rainer Ernst2012
  3. Nicholas Devito2019
  4. Bruce Harmon2020
  5. Georgiy Kovalyov2022

Chief operating officer

  1. Satishchandran Chandrasekhar2020
2010201520202025
Board members and other officers (21)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerGeorge Kovalyov named May 10, 2023 to May 19, 202342
  • Executive OfficerAmy Chandler named Oct 19, 202143
  • Executive OfficerRoger Schaller named Oct 19, 202143
  • DirectorNilesh Patel named May 10, 2023 to May 19, 202342

Former names

  • MARIZYME INCSep 12, 2018 to May 10, 20232
  • GBS Enterprises IncAug 30, 2010 to Jun 27, 20182
  • Swav Enterprises Ltd.Oct 16, 2007 to Aug 18, 20102

Timeline

  1. Apr 17, 20268-K Entered a material agreement; Bankruptcy or receivership; Completed an acquisition or sale44
  2. Mar 4, 20258-K Earlier financial statements no longer reliable45
  3. Jan 31, 20258-K Earlier financial statements no longer reliable46
  4. Jul 18, 20248-K Entered a material agreement; New debt or obligation47
  5. May 6, 20248-K Regulation FD disclosure48
  6. Feb 6, 20248-K Executive or director change49
  7. Dec 28, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares50
  8. Nov 21, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares51
  9. Oct 24, 20238-K Executive or director change52
  10. Oct 23, 20238-K Regulation FD disclosure53
  11. Oct 6, 20238-K Regulation FD disclosure54
  12. Oct 4, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares55
  13. Jan 6, 2022New chief executive David Barthel becomes CEO14
  14. Dec 3, 2020New chief executive Neil J. Campbell becomes CEO16
  15. Sep 10, 2020New chief executive James Sapirstein becomes CEO15
  16. Oct 28, 2019New chief executive Nicholas Devito becomes CEO17
  17. May 7, 2010New chief executive Joerg Ott becomes CEO18
  18. Sep 21, 2009New chief executive Sandy J. Masselli Jr. becomes CEO19

Filings

107 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 36 major events, 21 insider forms, 2 large holders, 4 private raises, 29 other. The latest 20:

  1. Apr 17, 20268-K EDGAR
  2. Mar 5, 202510-Q EDGAR
  3. Mar 4, 20258-K EDGAR
  4. Feb 6, 202510-K/A EDGAR
  5. Jan 31, 20258-K EDGAR
  6. Aug 14, 202410-Q EDGAR
  7. Jul 18, 20248-K EDGAR
  8. May 28, 202410-Q EDGAR
  9. May 15, 2024NT 10-Q EDGAR
  10. May 13, 202410-K EDGAR
  11. May 6, 20248-K EDGAR
  12. Apr 1, 2024NT 10-K EDGAR
  13. Feb 6, 2024424B3 EDGAR
  14. Feb 6, 20248-K EDGAR
  15. Dec 29, 2023424B3 EDGAR
  16. Dec 28, 20238-K EDGAR
  17. Dec 28, 20234 EDGAR
  18. Nov 22, 2023424B3 EDGAR
  19. Nov 21, 20238-K EDGAR
  20. Nov 16, 2023424B3 EDGAR

The 107 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 3 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 29, 2023Lichti Braeden10% ownerSale105,000$0.17$17.9KForm 4
Aug 29, 2023Lichti Braeden10% ownerBuy105,000$0.17$17.9KForm 4
Jul 7, 2023Lichti Braeden10% ownerSale97,000$0.10$9.7KForm 4
Jul 7, 2023Lichti Braeden10% ownerBuy97,000$0.10$9.7KForm 4
Jun 29, 2023Lichti Braeden10% ownerSale106,327$0.09$9.6KForm 4
Jun 29, 2023Lichti Braeden10% ownerBuy106,327$0.09$9.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 15, 2023Raised $1 million in a private offering of equity Form D: $10 million offered in all Form D
  2. Apr 18, 2023Raised $265,216 in a private offering of equity Form D: 4 investors so far Form D
  3. May 27, 2021Raised $1.2 million in a private offering of debt Form D: $10 million offered in all Form D
  4. May 27, 2021Raised $1.2 million in a private offering of debt Form D: $10 million offered in all Form D

SEC filer profile

How MARIZYME, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMARIZYME, INC.1
  • CIK0001413754
  • Employer ID (EIN)82-54648631
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address555 Heritage Drive, Suite 205, Jupiter, FL 334581
  • Phone561-935-99551
  • Shares outstanding131,793,088 as of Mar 5, 202511
  • Public float$3.3M as of Jun 30, 20234
  • On EDGAR sinceOct 16, 20071
  • Filings384 in all: 8-K (103), 4 (41), 10-Q (38), 3 (32), 10-Q/A (20), NT 10-Q (15), 8-K/A (14), 10-K (12)1
    All 40 form types

    10-K/A (11), NT 10-K (10), S-1/A (9), UPLOAD (8), 424B3 (7), CORRESP (7), D (6), SC 13D (6), SC 13G (5), SC 13D/A (4), DEF 14A (3), PRE 14A (3), S-1 (3), 10-12G/A (2), DEF 14C (2), DEFA14A (2), EFFECT (2), PRE 14C (2), RW (2), S-8 (2), SC 14F1 (2), 10-12G (1), 10KSB (1), 15-12G (1), 4/A (1), 8-A12G (1), AW (1), D/A (1), DEFR14A (1), SB-2 (1), SB-2/A (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) May 13, 2024
    Quarterly report (10-Q) Mar 5, 2025
    Proxy statement (DEF 14A) Jun 23, 2023
    Latest 8-K (8-K) Apr 17, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57